NCT01049191

Brief Summary

Osteoporosis is a common disorder of compromised bone strength causing 40-50% of women and \~25% of men to sustain fragility fractures during their lifetime. The reduction of bone strength in osteoporotic people results from loss of bone density and deterioration of bone quality. Bone quality is a complex amalgamation including macro- and micro-architecture, mineralization, turnover and damage accumulation. Currently, medications to reduce fracture risk are prescribed primarily on the basis of bone mineral density (BMD) measurement. Unfortunately, currently available BMD measurement technologies do not detect the aforementioned properties of bone quality; as such, less than half of individuals who sustain osteoporotic fractures are classified as "osteoporotic" by currently available diagnostic tools. Clearly, measures to enhance identification of those at high fracture risk are needed. High-resolution magnetic resonance imaging (HR-MRI) technology, such as that provided by MicroMRI, Inc., has outstanding potential to be such a tool. Therefore, our long-term goal is to evaluate and optimize the use of HR-MRI in fracture risk prediction; this pilot work is an essential step in attaining this goal. This research will investigate 72 postmenopausal women with normal or osteopenic BMD by dual-energy x-ray absorptiometry (DXA), 36 with prior low-trauma fractures will be compared with 36 age-, race- and BMD matched women without fracture. We hypothesize that 1.) Women with fractures will have evidence of microarchitectural deterioration on HR-MRI and 2.) Newly developed, more rapid MRI sequences designed at the UW will provide similar trabecular microstructure information more rapidly than the currently used, albeit investigational, technology produced by MicroMRI, Inc. Our specific aims are to a) Evaluate differences in MicroMRI parameters of trabecular microstructure (bone volume fraction, trabecular thickness, surface/curve ratio and erosion index) between age-, race- and BMD-matched postmenopausal women with and without fracture; b.) Correlate T2\* relaxation time (a rapid indirect MRI measure of trabecular density and microstructure) with BMD measured by DXA, and microstructural parameters measured by MicroMRI. As an exploratory aim we will investigate HR-MRI parameters of trabecular microstructure obtained using a newly developed, rapid MRI sequence referred to as IDEAL-FSE with parameters obtained using the currently available MicroMRI, Inc. sequence.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
78

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2008

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2008

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

January 12, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 14, 2010

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
Last Updated

October 5, 2015

Status Verified

July 1, 2010

Enrollment Period

1.6 years

First QC Date

January 12, 2010

Last Update Submit

October 1, 2015

Conditions

Keywords

OsteoporosisFracturemicroMRIBone architectureBone matrixBone and BonesMagnetic Resonance Imaging

Outcome Measures

Primary Outcomes (1)

  • Evaluate difference in MicroMRI parameters of trabecular microstructure (bone volume, surface/curve ratio and erosion index) between age-, race- and BMD-matched postmenopausal women with and without fracture.

    18 months

Secondary Outcomes (1)

  • Correlate T2* relaxation time (a rapid indirect MRI measure of trabecular density and microstructure) with BMD measured by DXA, and microstructural parameters measured by MicroMRI.

    18 months

Study Arms (2)

Fracture

Subjects experiencing a prior osteoporotic fracture.

Control

These will be age and bone density matched controls to the fracture group.

Eligibility Criteria

Age50 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Seventy-two postmenopausal volunteers age ≥ 50 years will be recruited from existing databases of \~3500 women with expressed interested in research. All will have normal BMD or osteopenia (T-score \> -2.5 at the L1-4 spine, proximal femur and 1/3rd radius) by DXA. Thirty-six will have sustained a "fragility" fracture of the spine, hip or wrist, defined as a fracture occurring with everyday activities including a fall from standing height or less. Historical radiographic documentation of fracture will be obtained. Thirty-six women without fracture will serve as age- race- and BMD-matched controls. Age will be matched to within 6 months; BMD in grams/cm2 at the non-dominant ultra-distal radius will be matched to within 5%.

You may qualify if:

  • Postmenopausal women volunteers age ≥ 50 years
  • normal BMD or osteopenia (T-score \> -2.5 at the L1-4 spine, proximal femur and 1/3rd radius) by DXA.
  • sustained a "fragility" fracture of the spine, hip or wrist, defined as a fracture occurring with everyday activities including a fall from standing height or less.
  • Historical radiographic documentation of fracture will be obtained.
  • Criteria as defined above without prior fracture, age and bone density matching a participant in the fracture group

You may not qualify if:

  • metabolic bone disease
  • malignancy
  • renal failure
  • use of medications which alter bone turnover
  • diseases/conditions leading to the non-dominant arm disuse
  • contraindications to MRI.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Wisconsin Hospitals and Clinics

Madison, Wisconsin, 53705, United States

Location

University of Wisconsin Osteoporosis Clinical and Research Program

Madison, Wisconsin, 53705, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples are being collected to obtain chemistry panel and test related to skeletal status. These samples will not be retained or stored after these analyses are completed.

MeSH Terms

Conditions

OsteoporosisFractures, Bone

Condition Hierarchy (Ancestors)

Bone Diseases, MetabolicBone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic DiseasesWounds and Injuries

Study Officials

  • Richard Kijowski, MD

    University of Wisconsin Department of Radiology

    PRINCIPAL INVESTIGATOR
  • Neil C Binkley, MD

    University of Wisconsin Osteoporosis Clinical Research Center

    STUDY DIRECTOR
  • Michael J Tuite, MD

    University of Wisconsin Department of Radiology

    STUDY DIRECTOR

Study Design

Study Type
observational
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 12, 2010

First Posted

January 14, 2010

Study Start

October 1, 2008

Primary Completion

May 1, 2010

Study Completion

May 1, 2010

Last Updated

October 5, 2015

Record last verified: 2010-07

Locations